KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Gross Profit: 2020-2025

Historic Gross Profit for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to -$9.5 million.

  • Recursion Pharmaceuticals' Gross Profit fell 167.93% to -$9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.8 million, marking a year-over-year decrease of 212.79%. This contributed to the annual value of $13.6 million for FY2024, which is 584.15% up from last year.
  • Recursion Pharmaceuticals' Gross Profit amounted to -$9.5 million in Q3 2025, which was down 914.07% from -$938,000 recorded in Q2 2025.
  • Recursion Pharmaceuticals' Gross Profit's 5-year high stood at $14.0 million during Q3 2024, with a 5-year trough of -$9.5 million in Q3 2025.
  • For the 3-year period, Recursion Pharmaceuticals' Gross Profit averaged around -$176,909, with its median value being -$314,000 (2023).
  • Examining YoY changes over the last 5 years, Recursion Pharmaceuticals' Gross Profit showed a top increase of 4,170.64% in 2024 and a maximum decrease of 916.63% in 2024.
  • Quarterly analysis of 5 years shows Recursion Pharmaceuticals' Gross Profit stood at $2.5 million in 2021, then grew by 11.96% to $2.8 million in 2022, then slumped by 64.39% to $1.0 million in 2023, then crashed by 916.63% to -$8.2 million in 2024, then tumbled by 167.93% to -$9.5 million in 2025.
  • Its last three reported values are -$9.5 million in Q3 2025, -$938,000 for Q2 2025, and -$7.1 million during Q1 2025.